Comanche Biopharma is developing novel therapies for safer pregnancies. Its lead program, CBP-4888, is an investigational siRNA therapeutic targeting sFlt-1 overproduction, a key driver of preeclampsia. Australian sites are now enrolling patients with preterm preeclampsia in the first clinical evaluation of CBP-4888 during pregnancy. https://comanchebiopharma.com/
All travellers must have a valid visa BEFORE travelling to Australia and apply for your visa at least 6-8 weeks prior to commencement of your travel. Apply now
d
h
m
s
All travellers must have a valid visa before TRAVELLING to Australia and apply for your visa at least 6-8 weeks prior to commencement of your travel. Apply now
d
h
m
s
Hosted by
